14915 Broschart Road
182 articles with GlycoMimetics, Inc.
GlycoMimetics, Inc. announced that Chief Executive Officer Rachel King will provide a corporate update at two upcoming investor relations conferences in New York, NY in September.
8/5/2019The goal of the trial was to evaluate the efficacy and safety of the drug in patients six years of age and older with SCD who were hospitalized for a vaso-occlusive crisis and required treatments with intravenous opioids.
GlycoMimetics Reports Top-line Results From Pfizer’s Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease
GlycoMimetics, Inc. reported that Pfizer Inc. announced that the Phase 3 Rivipansel: Evaluating Safety, Efficacy and Time to Discharge pivotal study did not meet its primary or key secondary efficacy endpoints.
GlycoMimetics, Inc. reported its financial results for the quarter ended June 30, 2019 and highlighted recent business achievements.
The dial-in number for the conference call is (844) 413-7154 (U.S. and Canada) or (216) 562-0466 (international) and entering passcode 8268638.
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a corporate update at the Jefferies 2019 Healthcare Conference, on June 5 at 2:00 p.m. ET. in New York, NY.
GlycoMimetics, Inc. Announces Enrollment Completed for Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease
Since completion of the Phase 2 clinical trial, Pfizer, has been responsible for clinical development of rivipansel, including the RESET clinical trial.
GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the quarter ended March 31, 2019 and highlighted recent company achievements
GlycoMimetics Bolsters Executive Team with Appointment of Dr. Eric Feldman as Vice President, Clinical Development, and Christian Dinneen-Long as Vice President, Corporate Counsel
GlycoMimetics, Inc. announced the addition of two senior executives to its executive management team.
GlycoMimetics, Inc. announced that it will host a conference call and webcast to report its first-quarter 2019 financial results on Thursday, May 2, 2019, at 8:30 a.m. ET.
GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML
Evaluating previously untreated newly diagnosed adults with acute myeloid leukemia (AML) who are fit for intensive chemotherapy
GlycoMimetics Announces Publication of Nature Cell Biology Paper Supporting Recently Announced Clinical Trial of GMI-1359
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the publication of a paper in Nature Cell Biology that describes how tumor cells engage specific stromal components, most notably E-selectin, for propagation and outgrowth.
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced plans to initiate a clinical trial of GMI-1359 in breast cancer patients whose tumors have spread to bone
GlycoMimetics, Inc. announced that senior management will present corporate updates at two upcoming investor conferences in April.
March is National Women’s Month with March 8 specifically designated as International Women’s Day. Although this is not remotely a comprehensive list, BioSpace recognizes these 10 women (in no particular order) as being especially influential in the biopharma industry.
GlycoMimetics, Inc. announced that Chief Executive Officer Rachel King will provide a company overview at the Cowen and Company 39th Annual Health Care Conference in Boston, on Tuesday, March 12, 2019, at 9:20 a.m. ET.
Initiated first company-sponsored Phase 3 pivotal trial of uproleselan in relapsed/refractory acute myeloid leukemia (AML) at sites in U.S., Europe, Canada and Australia
Current Board Member Tim Pearson to become Board Chair effective at the close of the company’s annual meeting on May 17, 2019
GlycoMimetics, Inc. announced that it will host a conference call and webcast to report its fourth quarter and fiscal year 2018 financial results on Wednesday, March 6, 2018, at 8:30 a.m. ET.
GlycoMimetics Posters at 60th ASH Annual Meeting Highlight Preclinical Data on Two New Proprietary Drug Candidates
GlycoMimetics, Inc. shared at the 60th American Society of Hematology (ASH) Annual Meeting yesterday two posters with preclinical data presentations: on GMI-1687, the company’s highly potent E-selectin antagonist that is bioavailable via subcutaneous administration, and GMI-1757, the company’s dual-function E-selectin/galectin-3 antagonist.